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Summary Monoclonal antibodies were raised against prostate-specific antigen (PSA) by immunization with purified free PSA, i.e. not in
complex with any protease inhibitor (F-PSA) and PSA in complex with a,-anti-chymotrypsin (PSA-ACT). Epitope mapping of PSA using the
established monoclonal antibody revealed a complex pattern of independent and partly overlapping antigenic domains in the PSA molecule.
Four independent antigenic domains and at least three partly overlapping domains were exposed both in F-PSA and in the PSA-ACT
complex, while one antigenic domain was specific for F-PSA. The different domains contained both continuous and discontinuous epitopes.
The combination of antibodies recognizing antigenic domains exposed both in F-PSA and PSA-ACT made it possible to develop several
highly sensitive sandwich immunoassays fordetermination of total PSA, i.e. F-PSA + PSA-ACT, with the same molar response for F-PSA and
PSA-ACT. Assays specific for F-PSA (cross-reactivity between F-PSA and PSA-ACT < 1%) were developed by the combination of
antibodies recognizing epitopes exposed only in F-PSA and antibodies recognizing epitopes exposed both in F-PSA and PSA-ACT.
Keywords: prostate-specific antigen; prostate-specific antigen in complex with a1-anti-chymotrypsin; free prostate-specific antigen; epitope
mapping; immunoassays
Human prostate-specific antigen (PSA) is a 32 to 33-kDa single-
chain glycoprotein, containing 7% N-linked carbohydrates,
produced in the secretory epithelium ofthe prostate gland (Wang et
al, 1979). Undernormal conditions, PSA is secreted into the seminal
fluid andis involvedin the liquefaction ofthe seminalcoagulum and
activation ofsperm motility afterejaculation (Lilja, 1985; Liljaetal,
1987). The serum concentration is normally low, andelevated serum
PSA levels are indicative of prostate pathology or trauma. PSA is
widely used in the clinical management of prostate cancer and is
regarded as the most useful tumour marker for management of
patients with carcinoma ofthe prostate (Oesterling, 1991).
PSA has been characterized as a serine protease with restricted
chymotrypsin-like specificity belonging to the human kallikrein
gene family (Lilja, 1985; Watt et al, 1986; Akiyama et al, 1987;
Lundwall and Lilja, 1987; Schedlich et al, 1987; Lundwall, 1989;
Riegman et al, 1989 Christensson et al, 1990). Enzymatic active
PSA forms stable complexes with the protease inhibitors a2-
macroglobulin (o2M) and ao-anti-chymotrypsin (ACT), preg-
nancy zone protein and protein C inhibitor (PCI) (Christensson et
al, 1990; Christensson, 1993). The PSA-ac2M complex is not
determined in conventional two-site sandwich immunoassays but
can be detected by Western blotting after SDS-PAGE (Zhou et al,
1993). The dominating portion of PSA in serum determined in
conventional immunoassays occurs in a complex with ACT (Lilja
et al, 1991; Stenman et al, 1991; Wood et al, 1991).
Large variations in the proportion of F-PSA have been found
between different individuals, and determination of the ratio of
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F-PSA to total PSA (i.e. F-PSA + PSA-ACT) has been shown to
improve the diagnostic sensitivity and specificity for prostate
cancer compared with determination of total PSA alone
(Christensson et al, 1993). Specific determination of PSA-ACT
has alsobeenreported to increase the sensitivity and specificity for
prostate cancer (Stenman et al, 1991; Leinonen et al, 1993).
This paper describes the establishment of MAb against PSA,
characterization ofthe antigenic domains of PSA using the estab-
lished MAb and development ofimmunoassays for specific deter-
mination ofdifferent serological forms ofPSA.
MATERIALS AND METHODS
Purification of PSA, PSA-ACT and PSA-a2M complex
PSA was purified from pooled seminal plasma from healthy
volunteers by ion-exchange chromatography and gel chromatog-
raphy, essentially as described (Christensson et al, 1990).
Homogeneity of the purified PSA was tested by SDS-PAGE of
unreduced PSA on 10% homogeneous gels stained with Comassie
brilliant blue. The complex between PSA and ACT (Biodesign,
MD, USA) was obtained by incubation of purified PSA and ACT
(Christensson et al, 1990) and purification by size exclusion chro-
matography on Sephacryl S-100 (Pharmacia LKB Biotechnology,
Sweden) eluted with phosphate-buffered saline (PBS) pH 7.1. The
elution was monitored by determination ofPSA immunoactivity in
the eluted fractions using PSA Delfia kit (Wallac Oy, Turku,
Finland). Peak fractions corresponding to a molecular size of
approximately 100 kDa and approximately 30 kDa were pooled
and concentrated by ultra filtration in an Amicon UF cell and
YMIO filter (Amicon, MA, USA). The PSA-ax2M complex was
formed by incubation ofhuman a2M (Biodesign, MD, USA) with
twofold molar excess of PSA for 4 h at 37°C and used without
789790 0 Nilsson etal
further purification. The concentration of the PSA-a2M complex
was estimated by calculation ofthe PSA concentration before and
afterincubation with a2M. The 'PSA-cx2M fraction' was estimated
to contain 8 jg 1-1 F-PSA and approximately 34 jig 1-' PSA-a2M,
i.e. the fraction contained 42 jig 1-1 PSA before incubation with
ct2M and 8 ,ug 1-' PSA after incubation; thus the concentration
of PSA-o2M was estimated to be = 34 jig 1-1 (with respect to
PSA content).
Establishment of anti-PSA MAb
Female Balb/c mice, 5-6 weeks of age, were immunized i.p. with
approximately 10 jig of purified PSA in Ribi Adjuvant System
(Ribi ImmunoChem Res., MT, USA). The mice received four to
five booster doses with 5-10 jig of PSA-ACT in Ribi adjuvant
over 50-100 days. Three to five days after the final booster dose,
hybridomas were obtained by fusion of spleen cells with the Ag8
myeloma cell line (ATCC, Rockville, MD, USA) (Lindholm et al,
1983). The hybridomas were screened by incubation ofhybridoma
medium in microtitre plates (Nunc, Denmark) coated with affinity
purified goat anti-mouse IgG+M (Jackson Immunoresearch
Laboratory, PA, USA); incubation of antibody-coated microtitre
plates with 100 jil ofPSA (100 jig 1-') overnight; and detection of
positive clones by incubation with polyclonal rabbit anti-human
PSA Ig and HRP swine anti-rabbit Ig (Dako AS, Denmark).
Positive clones were further screened with purified PSA-ACT
complex. The selected hybridomas were cloned twice by limiting
dilution; monoclonal antibodies were produced by in vitro cultiva-
tion in DMEM (Gibco, UK) containing 5% fetal calf serum
(HyClone Laboratories, UT, USA) and purified by ProSep protein
A affinity chromatography, according to the manufacturer's
instructions (BioProcessing, UK). The isotype of the monoclonal
antibodies was determined in a solid-phase ELISA with goat anti-
mouse Ig (G+A+M) as catching antibody and peroxidase-labelled
isotype-specific rabbit anti-mouse IgGI, IgG2a, IgG2b, IgG3, IgA
and IgM as detecting reagents (Zymed Laboratories, CA, USA).
Determination of epitope specificity
The specificity of the hybridomas was analysed by determination
ofthe reactivity with purified PSA, PSA-ACT and ACT in ELISA
assays, competitive binding inhibition studies, dose-response
curves ofdifferent MAb combinations andWestern blot ofreduced
and unreduced PSA and of unreduced PSA-x2M separated by
SDS-PAGE. The epitope specificity ofthe MAbs was further char-
acterized by determination of their potential to inhibit the PSA
enzyme activity against a low molecular peptide substrate.
ELISAs
Anti-PSA MAb solid phase was obtained by incubation of each
purified anti-PSA MAb (5g ml-') in 0.2 M sodium dihydrogen
phosphate overnight at 22-24°C in Nunc MaxiSorp C12 or C8
immunomodule plates (Nunc, Denmark); after washing, non-
specific binding was blocked by incubation with 6% sorbitol,
0.5% bovine serum albumin (BSA) in Tris-buffered saline (TBS)
(pH 7.75).
The gross specificity of the MAbs was determined by incuba-
tion of25,u1 of serial dilution ofpurified PSA, PSA-ACT or ACT
(500-0 jig 1-1 with the addition of 100 jil ofincubation buffer (lOg
1-' BSA, 0.5 g 1-' bovine Ig and 0.1 g l-' Tween 20 in TBS pH 7.75)
in duplicates for 1 h in the anti-PSA MAb-coated microtitre plates
(MTPs); after washing, the wells were incubated with polyclonal
rabbit anti-human PSA Ig (or polyclonal rabbit anti-human ACT
Ig when ACT was used as antigen), and absorbance was deter-
mined at 450 nm after incubation with HRP swine anti-rabbit Ig
and orthophenyl diamine (OPD) substrate.
Competitive binding-inhibition assays
The anti-PSA MAbs were labelled with N1-DTTA europium (Eu)
chelate (Wallac Oy, Turku, Finland) to specific activities of 4-7
Eu/IgG as previously described (Hemmila et al, 1983). The
competitive binding-inhibition assays were performed as follows:
100 jl of PSA (100 jig 1-1) was incubated for 1 h in the anti-PSA
MAb-coated MTP; after washing, 25 jl of unlabelled anti-PSA
MAb plus 100 jl Eu Anti-PSA MAb (1 jg ml-') were added in
triplicate and incubated for 1 h. The Eu fluorescence was deter-
mined in an Arcus 1230 fluorometer after addition of 200 jil
Enhancement Solution. The inhibition was calculated as per cent
decrease in signal in the presence of unlabelled anti-PSA MAb
compared with the signal without unlabelled anti-PSA MAb. The
inhibition assays were performed in two steps; firstly, 'screening'
with the concentration of inhibitor constant at S jig ml' and,
secondly, determination of inhibition curves using 100-0.16 jg
ml' of inhibiting MAb. The inhibition studies were performed
with the hybridomas reacting with F-PSA and F-PSA + PSA-ACT.
MAbs giving total cross-inhibition with each other (i.e. the
same antibody combination giving >80% inhibition both as
inhibiting and labelled MAb) were included into the same anti-
body group. Differences in dose-response, inhibition with
different MAb combinations and reactivity in Western blot were
used as criteria for separation ofthe MAbs into subgroups.
Inhibition of polyclonal Anti-human PSA Ig.
The inhibition ofthe binding of a polyclonal rabbit anti-PSA anti-
serum to solid-phase immobilized PSA by the anti-PSA MAbs
was tested in a similar competitive binding-inhibition assay as
described above. PSA was incubated in the anti-PSA MAb-coated
MTP, and 100 jil ofthe Anti-PSA MAbs (10 jig ml-') was added in
triplicate; after 30 min incubation, 100 jil ofpolyclonal rabbit anti-
human-PSA Ig (Dako AS) diluted 1:500 was added, and the incu-
bation continued for another 30 min; after washing, HRP-swine
anti-rabbit Ig was added and incubated for 30 min. The inhibition
was tested with individual anti-PSA MAb and different combina-
tions of the anti-PSA MAb, but the final concentration of
inhibiting MAb was kept constant at 10jg ml' in all experiments.
Inhibition of PSA enzyme activity with anti-PSA MAb
The effect on the PSA proteolytic activity was studied by inhibi-
tion by anti-PSA MAb of the hydrolysis of the chromogenic
peptide substrate S-2586 (MeO-Suc-Arg-Pro-Tyr-pNA), Chromo-
genix AB, Molndal, Sweden. The hydrolysis ofS-2586 peptide by
PSA was performed essentially as described by Christensson et al
(1990) but was adapted to be performed in microtitre plates. In the
assay, 2.5-5 jig ofpurified PSA (or seminal plasma corresponding
to 2.5-5 jig PSA) in 100 jil of50 mm Tris-HCI, 0.IM sodium chlo-
ride pH 7.8, was incubated together with 0.01-75 jig of anti-PSA
MAb for 30 min, and then 3-10 mm S-2586 substrate was added
and the hydrolysis was determined at room temperature during a
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period of20 min. In control experiments, the hydrolysis was tested
by incubation of S-2586 in (a) buffer without PSA or anti-PSA
MAb and (b) buffer with anti-PSA MAb without PSA. The hydrol-
ysis of the S-2586 substrate was determined at 405 nm every 30s
for 20 min in a Molecular Device vMax microtitre plate reader.
The inhibition of the hydrolysis by the anti-PSA MAb was calcu-
lated as the difference in Abs4O5nm between 0 and 20 min with
and without addition ofanti-PSA MAb.
Dose-response and specificity of different anti-PSA
MAb combinations
Dose-response curves were determined for all combinations ofthe
anti-PSA MAb as follows: 25 pl ofantigen (500, 100, 10, 5, 1 and
0 ng ml- F-PSA, PSA-ACT or ACT) plus 100 gl of incubation
buffer was incubated in duplicates for 30-60 min in microtitre
plates coated with anti-PSA MAb; after washing, 100 pl of Eu
anti-PSA MAb (1 jg ml-') was added, and the incubation was
continued for an additional 30-60 min. The Eu fluorescence was
determined in an Arcus flurorometer after additional washings and
incubation with 200 pl Enhancement Solution.
The antigen specificity of the different MAb combinations was
confirmed by determination ofdose-response curves with purified
F-PSA, PSA-ACT and ACT and by determination of the PSA
immunoactivity in eluted fractions from S-100 gel chromatog-
raphy ofa mixture ofF-PSA and PSA-ACT complex. The prelim-
inary clinical specificity ofthe different assays was compared with
PSA Delfia kit in samples from subjects with benign prostate
hyperplasia and prostate cancer.
The relative response for F-PSA and PSA-ACT ofdifferent total
PSA assays was analysedessentially as describedpreviously (Liljaet
al, 1991) - a control sample with seminal plasma containing 100 ,ug
ofPSA in 2 ml PBS (pH 7.2), and a test sample containing seminal
plasma, 100 jg ofPSA and500 jig ofACTin 2 ml PBS (pH 7.2) was
incubated for 2 h at 37'C. Thereafter the two samples were analysed
in quadruplicate in the respective assay after dilution 1:200 with
incubation buffer.
SDS-PAGE and western blot
The binding of the antibodies to reduced and non-reduced PSA
was analysed by Western blot analysis after SDS-PAGE. Purified
PSA was reduced with mercaptoethanol as follows: PSA was
mixed in a ratio of 1:1 (v/v) with sample buffer (50 mM Tris HCl
(pH 6.8) containing 0.2% mercaptoethanol, 15% glycerol, 5%
pyronin Y and 3% SDS) and incubated for 5 min in a boiling water
bath. For analysis of non-reduced PSA mercaptoethanol was
omitted from the sample buffer. After denaturation (± reduction)
the sample, 2 jig of PSA per lane, was immediately separated on
homogeneous 10% polyacrylamide gels in A Bio-Rad Protean II
electrophoresis cell (Bio-Rad Laboratories, CA, USA) at 25-35
mA per gel using 20 mM Tris pH 8.3, 14 g 1-' glycine, 1 g 1-1
sodium dodecyl sulphate (SDS) as electrophoresis buffer. The
reactivity with PSA-a2M was tested by SDS-PAGE of unreduced
denaturated PSA-a2M on a 5-15% gradient polyacrylamide gel.
After electrophoresis, the samples were electroblotted onto BA85
nitrocellulose membrane (Schleicher & Schull, Germany) using a
Trans-Blot Cell (Bio Rad Laboratories, CA, USA). The NC
membrane was blocked for 2 h in 3% TBS-BSA, washed twice for
10 min in tris buffered saline containing Tween 20 (TTBS), cut
into strips and incubated with the anti-PSA MAb (5 jig ml-') in
TBS-BSA for 2 h; after three 10-min washes in TTBS, the strips
were incubated with HRP rabbit anti-mouse Ig for 1 h and visual-
ized using 4-chloronaphthol (Bio-Rad Laboratories, CA, USA).
RESULTS
In total, 33 different hybridomas were selected because of the
apparent high affinity and used forproduction ofMAb. All but one
(IgG2a) produced MAb ofthe IgGI isotype.
ELISA against purified PSA, PSA-ACT and ACT
Based on the reactivity with F-PSA, PSA-ACT and ACT, the
hybridomas were divided into three major groups: group A, 17
Table 1 Antigenic domains recognized by anti-PSA MAb
Group A: epitopes exposed in both free PSA and PSA-ACT complex
I 11 III IV V VI VIl
a b a b a b a b
PSA 8 PSAl0 PSA66 PSA67 PSA29 PSA36 PSA12 PSA27 PSA42 PSA54 PSA74
PSA13 PSA33 PSA71 PSA45
PSA31 PSA69
Group B: epitopes exposed only in free PSA Group C: epitopes exposed in ACT
I II
a b
PSA6 PSA17 PSA25 PSA55 PSA57
PSA30 PSA19 PSA63 PSA60
PSA20 PSA53 PSA68
PSA61 PSA70
PSA64 PSA75
The Anti-PSA Mabs were established and the specificity determined as described in Materials and methods.
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Figure 1 (A) Inhibition of group Al MAb with MAb-recognizing epitopes exposed both in F-PSA and PSA-ACT. (B) Inhibition of group Al MAb with MAb-
recognizing epitopes exposed in F-PSA. The inhibition studies were performed as described in Materials and methods. In A the PSA30 MAb was used for the
initial binding of PSA to the solid phase. and, in B PSA66 MAb was used for the binding of PSA to the solid phase. (C) Dose-response of sandwich assays
using PSA 20 MAb as solid-phase coated in microtitre plates and group Al MAb as europium-labelled tracer. The assays were performed as described in
Materials and methods
hybridomas producing MAbs reacting with both F-PSA and
PSA-ACT, but without reactivity with ACT; group B, six
hybridomas reacting only with F-PSA; and group C, ten
hybridomas reacting with PSA-ACT but not with F-PSA. The
group C MAb detected epitopes in the ACT portion of the
PSA-ACT complex and purified ACT, as shown in the ELISAs
with pure ACT and anti-ACT as tracer (data not shown).
Competitive binding-inhibition assays and
dose-response of sandwich pairs of anti-PSA MAb
Based on the inhibition studies and determination of dose-
response of different sandwich immunoassays, the antibodies of
group A and B could be divided into nine groups (Table 1).
The Group A antibodies were separated into antigenic domains
based on the results from the cross-inhibition studies and
dose-response curves of sandwich immunoassays (see criteria for
separation into different groups in Materials andmethods). The anti-
bodies PSA8, PSAlO, PSA13, PSA31, PSA33 and PSA69 MAbs
showed a cross-inhibition of > 80% between each other and were
included as group Al (Figure IA). The results ofthe inhibition with
group B MAbs (Figure iB) and the dose-response curves using
PSA17, PSA19 or PSA20 as solid-phase or tracer MAbs in sand-
wich immunoassays (Figure IC) indicatedthatthe antibodies should
be separated into two subgroups: group AMa consisting of PSA8,
PSA13 and PSA31 and group AIb PSAO0, PSA33 and PSA69.
The PSA66, PSA67 and PSA71 MAbs showed a cross-inhibi-
tion of > 80% and were included as group All (data not shown).
Based on the differences in inhibition pattern with MAbs of group
AIII (data not shown) and reactivity with reduced PSA (see Figure
3), the PSA66 and PSA71 MAbs were included in group Alla, and
PSA67 MAb was included in group AlIb.
The PSA29, PSA36 and PSA45 MAbs inhibited each other
> 80% and were included as group AIII. These MAbs were also
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Figure 2 (A) Inhibition of group B MAb with MAb-recognizing epitopes exposed in both F-PSA and PSA-ACT. (B) Inhibition of group B MAb with MAb-
recognizing epitopes exposed only in F-PSA. The inhibition studies were performed as described in Materials and methods. In (A) PSA30 MAb or PSA 19 MAb
was used for the initial binding of PSA to the solid phase. (B) PSA66 MAb was used for the binding of PSA to the solid phase
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Figure 3 PSA was reduced with mercaptoethanol, separated by SDS-PAGE
on a 10% homogeneous PAGE, electroblotted to NC membranes and
immunodetected as described in Materials and methods. Lane REF
prestained molecular weight markers from the top phosphorylase B, 140
kDa; BSA, 87 kDa; ovalbumin, 48 kDa; carbonic anhydrase, 33.3 kDa;
soybean trypsin inhibitor, 28.6 kDa; lysozyme, 20.7 kDa; Lane Pab,
polyclonal rabbit anti-PSA; Lane Al a, PSAl 3 MAb; Lane Al b, PSA 10 MAb;
Lane All a, PSA66 MAb; Lane All b, PSA67 MAb; Lane AlII a, PSA29 MAb;
Lane Aill b, PSA36 MAb; Lane A IVa, PSA1 2 MAb; Lane A IV b, PSA27
MAb; Lane AV, PSA42 MAb; Lane A VI, PSA 54 MAb; Lane A VII, PSA74
Mab; Lane BI PSA30 MAb; Lane BIl a, PSA17 MAb; Lane BIl b, PSA25 MAb
divided into two subgroups based on differences in dose-response
curves and cross-inhibition pattern (e.g. see differences in inhibition
of group B MAb, Figure 2 A), group Allla consisting of PSA29
MAb and group Allb consisting of PSA36 and PSA45 MAbs.
The remaining group A MAbs were divided into four additional
groups: group AIV, PSA12 and PSA27 MAb; group AV, PSA42
MAb; group AVI, PSA54 MAb; and group AVII, PSA74 MAb.
The group B MAbs cross-inhibited each other by more than
80% (Figure 2B3). They were also inhibited =80% by group V and
VI, and a partial inhibition was also seen with group Ala MAb and
group Allla MAb (Fig 2A). However, the group B antibodies
could not inhibit the binding to PSA of these antibodies (data not
shown). Based on the recognition of reduced PSA, the PSA30 and
PSA6 MAbs (Figure 3) were included in group BI. The other F-
PSA-specific MAbs did not recognize reduced PSA and were
included in group BlI.
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Figure 4 MAbs of the different groups were mixed (total concentration 10 gg
ml-1), and the inhibition was performed as described in Material and
methods. In the figure, the mean + s.d. of triplicate analysis is shown
Competitive inhibition of polyclonal anti-human PSA
The different group A anti-PSA MAbs inhibited the polyclonal
anti-PSA Ig 19-47% each when tested as individual groups.
Combination of the different group A MAb led to a stepwise
increase in inhibition and combination of all group A anti-PSA
MAbs resulted in = 90% inhibition of the polyclonal anti-PSA Ig.
The group B anti-PSA MAbs inhibited polyclonal anti-PSA Ig =
20%. Combination of group A and B anti-PSA MAbs inhibited the
polyclonal anti-PSA Ig > 95% (Figure 4).
Inhibition of PSA proteolytic activity
Antibodies of group All and AllIb inhibited the PSA-mediated
proteolysis ofthe chromogenic substrate S-2586 by less than 50%,
while all other antibodies recognizing epitopes exposed both in
F-PSA and the PSA-ACT complex almost completely inhibited
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the hydrolysis. The antibodies specific for F-PSA all almost
completely inhibited the proteolytic activity ofPSA against S-2586
chromogenic peptide substrate.
Western blot of PSA and PSA-cc2M complex
Unreduced SDS denatured PSA was recognized by all group A
and B antibodies in Western blot after SDS-PAGE (data not
shown). The polyclonal anti-human PSA antiserum and MAbs of
group Alla, AIII, AIV, AVII and BI reacted with reduced PSA
(Figure 3). A very faint reactivity with reduced PSA was also seen
by Group AV and AVI MAbs, while Group Al, AIIb and BII
MAbs did not react with reduced PSA. Group AIII MAbs and
polyclonal anti-PSA reacted with fragments of PSA formed after
reduction ofthe 'nicked' forms ofPSA (Figure 3).
All PSA MAbs reacted with PSA-o2M in Western blot after
SDS-PAGE, and there were no obvious differences between group
A and group B MAbs in the recognition of PSA-a2M after SDS-
PAGE Western analysis (data not shown).
Design of sensitive equimolar-response assays for
determination of total-PSA
Sandwich assays with an apparent equimolar response for F-PSA
and PSA-ACT were designed using MAbs of Group AIb, Alla,
AIII, AV and AVII. In particular, sandwich assays using PSAlO,
PSA29, PSA36, PSA66 and PSA42 MAbs resulted in Delfia
assays with high sensitivity (lower limit of detection (LLD) <<
0.01 ,ug 1-1 using 25 ,ul of sample (LLD defined as the concentra-
tion corresponding to the signal of 2 x s.d. of six-replicate deter-
mination ofthe zero standard) and fast kinetics (30 + 30 min). The
prototype assays showed a good correlation with commercial
assays for determination ofPSA - coefficient ofcorrelation > 0.98
compared with PSA Delfia in 70 samples from subjects with BPH
and prostate cancer (data not shown).
The relative response in the sample with PSA and ACT incu-
bated for 2 h at 370C were 99± 3% (mean ± s.d.) ofthe response of
the control sample for the assays PSA1O-PSA66, PSA1O-PSA36,
PSA66-PSA36 andPSA66-PSA42 using 25g1 ofsample and 30 +
30 min incubation time. The PSA42-PSA29 assay showed a rela-
tive response of 84 ± 3% using 30 + 30 min incubation and 97 +
2% using 1 + 1 h incubation (Table 2).
Design of assays for determination of F-PSA
The MAbs of Group B could not be combined with each other in
sandwich assays. However, combination ofMAbs ofGroup B and
Group A resulted in assays specific for F-PSA. In particular,
combination of the Group B MAbs either as catching MAb or as
detecting MAb together with MAb PSA66 of Group AIla or PSA
36 MAb of Group AIIIb resulted in assays with high sensitivity.
The specificity of these assays, i.e. cross-reaction between F-PSA
and PSA-ACT, was << 1% determined either by response ofpuri-
fied PSA-ACT complex or determination of response in eluted
fractions corresponding to PSA-ACT after separation of F-PSA
and PSA-ACT by size exclusion chromatography on Sephacryl S-
100. The immunoassays using PSA42 and/or PSA54 either as
catching or detecting antibody in combination with the Group B
Mabs did not give any dose-response curves, and a poor
dose-response relationship was also seen with antibodies ofgroup
Ala and AllIa. This is in agreement with the fact that the PSA 42
Table 2 Relative response of different PSA assays
Samples % relative responsea
Assay Control Test
PSAl OPSA66b 100 102 ± 1.5
PSA10-PSA36 100 98± 2.1
PSA66-PSA36 100 100± 1.1
PSA66-PSA42 100 99± 1.4
PSA42-PSA29, 30 + 30 min 100 84 ± 2.5
PSA42-PSA29, 60 + 60 min 100 97 ± 0.9
PSAl -PSA30 100 59± 1.4
aThe signal in the control sample was assigned 100% and the signal in the
test sample was given as a percentage of the signal in the control sample;
bPSA1G-PSA66 indicates catching MAb-tracer MAb. The control sample
consisted of seminal plasma containing 100 9g of PSA in 2 ml of PBS and
incubated 2 h at 370C before analysis. The test sample consisted of seminal
plasma containing 100 jig of PSA plus 500 jg of ACT in 2 ml of PBS and
incubated for 2 h at 370C before analysis. The samples were diluted 1: 200
before analysis in quadruplicates in the respective IFMA prototype assay. All
assays used the following assay protocol unless otherwise stated in the
table: 25 Rl sample + 100 gl assay buffer, 30 min incubation; washing three
times; 100 gl of Eu-labelled tracer (1 jg ml-') incubation 30 min; washing six
times; 200 jl of enhancement solution and determination of Eu fluorescence
in an Arcus fluorometer.
and PSA54 MAbs almost completely inhibited and that the Ala
and Allla antibodies partly inhibited the binding of the group B
MAbs. The results indicated that the epitopes of these antibodies
may be located close to each other in the native PSA molecule.
Assays for determination of PSA-ACT
Using antibodies from Group A as catching MAbs and MAbs from
group C as detecting MAbs, it was possible to design two-step
sandwich assays for specific determination of the PSA-ACT
complex without (<< 1%) cross-reactivity with F-PSA (data not
shown).
DISCUSSION
The existence of different molecular forms of PSA in serum and
significant differences in the proportions of the serological forms
ofPSA between individuals (Lilja etal, 1991; Stenman et al, 1991;
Christensson et al, 1993) and between benign and malignant
prostate disease has further increased the importance ofwell-char-
acterized immunological reagents for standardization of PSA
immunoassays (Graves et al, 1990; Graves, 1993; Stamey et al,
1994) and for development ofassays for specific determination of
different forms of PSA.
In this paper, antigenic domains of PSA were characterized in
order to find optimal pairs of MAbs to be used in immunoassays
for determination ofF-PSA and total PSA (i.e. F-PSA+PSA-ACT
complex).
The epitope mapping indicated a complex pattern of eight to
nine unrelated and partly overlapping antigenic domains in PSA.
The complexity ofthe antigenic domains was further increased by
the existence of several epitopes within each domain (e.g. see
separation ofGroup Al into at least two subgroups, Figure lA-C).
In order to illustrate the possible relationship between the different
antigenic domains, a hypothetical 'map' of the antigenic domains
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Figure 5 The group A MAb recognized epitopes exposed both in F-PSA and
PSA-ACT, while the group B MAb recognized epitopes that were covered by
the ACT and only exposed in F-PSA. The figure gives an illustration of the
possible relation between the different domains recognized by the
established MAbs
of PSA was drawn (Figure 5). The Group A MAb recognizing
epitopes exposed both in F-PSA and in PSA-ACT detected four
unrelated domains (Al, AII, AIII and AV) that showed no or low
inhibition between each other and three antigenic domains partly
overlapped by the other domains.
One antigenic domain specific for F-PSA was detected which
consisted of at least one continuous and two probably discontin-
uous epitopes. In general, there was a clear distinction between the
antibodies that recognized exposed epitopes (i.e. epitopes that are
detected both in F-PSA and PSA-ACT) and hidden epitopes (i.e.
epitopes specific for F-PSA). However some antigenic domains
may be located close to the 'F-PSA specific' domain as a partial
inhibition of the F-PSA specific MAb was seen (e.g. group AIlla,
AV and VI). The close proximity of these epitopes and the F-PSA
domain was also supported by the fact that these antibodies
resulted in poor sandwich immunoassays with antibodies specific
for F-PSA, and that immunoassays using these antibodies did not
give equimolar assays for F-PSA and PSA-ACT during the exper-
imental conditions used. Lovgren et al (1995) and Pettersson et al
(1996) have characterized the epitopes ofdifferent PSA antibodies
by determination of the dose-response of different antibody
combinations (including the PSAIO, PSA36, PSA30, PSA6,
PSA19, PSA20 MAbs) with PSA, PSA-ACT, recombinant PSA
and recombinant hK2. Their studies showed that none ofthe anti-
bodies specific for F-PSA cross-reacted with hK2 and indicated
also that the PSAIO MAb and PSA36 MAb were specific for PSA,
i.e. without cross-reactivity with hK2. Preliminary in-house data
confirm these results and suggest that the separation of the Al and
AIII into subgroups would be dependent on difference in cross-
reactivity with hK2, i.e. group AIb and AllIb seem to be specific
for PSA, while antibodies of group Ala and AlIla may cross-react
with hK2 (unpublished observation).
Chu et al (1989) recognized two overlapping antigenic domains
using five MAbs, and Belanger et al, (1993) detected four anti-
genic domains using a large number of MAbs directed against
PSA. The MAbs did not completely inhibit a polyclonal anti-PSA
antiserum, in any of the studies, indicating that additional anti-
genic domains would be available. A complex pattern of overlap-
ping and distinct determinants of PSA was revealed by studying
all possible two-site immunoassays of 12 MAbs against PSA
(Pettersson et al, 1995). In our study, mixing MAbs of different
groups resulted in a step-wise increased inhibition of a polyclonal
rabbit anti-PSA antiserum, which clearly indicated that antibodies
of the different groups recognized different antigenic domains in
PSA. The initial screening procedure used in this study with unla-
belled PSA in solution may have exposed epitopes not exposed in
PSA-coated on solid phases or in labelled PSA, which may explain
the large number of different antigenic domains detected in this
study compared with previous studies. All studies indicate a
surprisingly complex epitope map of PSA, and further characteri-
zation of the reactivity with hKI, hK2 and different recombinant
forms of PSA would be needed in order to define true PSA-
specific antigenic domains.
Reduction of the five intra-chain S-S bonds in PSA and denatu-
ration with SDS will completely destroy the native three-dimen-
sional structure and also separate PSA into intact PSA and
'nicked' forms of PSA (i.e. PSA with internal cleavage of the
amino acid sequence which in the native form is held together by
the intra-chain S-S bonds). In this study, Western blot analysis of
reduced and non-reduced PSA by SDS-PAGE was used to separate
antibodies whose recognition of PSA was dependent only on the
linear sequence of amino acids (i.e. true continuous epitopes) and
those that were dependent on the three-dimensional structure of
PSA. Non-reduced PSA was recognized in the Western blot
analysis after SDS-PAGE by all MAbs, but there were clear differ-
ences in reactivity with reduced PSA between the MAbs.
Reactivity with reduced PSA strongly suggested that the epitopes
consisted of linear sequences of amino acids. The AIII MAbs (and
polyclonal antibody anti-PSA) reacted also with fragments of PSA
indicating that these antibodies also recognized 'nicked' forms of
PSA. Those MAbs that only recognized non-reduced PSA may
recognize discontinuous epitopes dependent on the three-dimen-
sional structure of the PSA molecule for binding, but it is not
possible to exclude the existence of continuous epitopes also
within this group. Although both reduced and non-reduced PSA
was recognized by some of the anti-PSA MAb, the reactivity was
clearly lower with the reduced form of PSA. Thus, the native
conformation of the PSA molecule was of major importance for
the binding to PSA of all MAbs.
The reaction between PSA and cx2-macroglobulin leads to total
encapsulation of the PSA molecule, and the PSA-a2M complex is
not detected in conventional immunoassays. Denaturation of the
PSA-x2M complex with SDS leads to the formation of two
subunits with an approximate molecular weight of 380 kDa and
exposure of the PSA moiety; and PSA-a2M has been detected in
human serum using SDS-PAGE (Zhou et al, 1993). Interestingly,
there was no difference in the recognition of PSA-ac2M in SDS-
PAGE between MAbs recognizing epitopes exposed both in F-
PSA and PSA-ACT and the MAbs recognizing epitopes exposed
only in F-PSA.
The proteolytic activity ofPSA against the S-2586 substrate was
almost completely inhibited by most antibodies, and only the anti-
bodies PSA66, PSA71, PSA67, PSA45 and PSA36 inhibited the
proteolysis by less than 50%. It was expected that the antibodies
recognizing epitopes specific for F-PSA would inhibit the prote-
olytic activity ofPSA, but it was expected less that most antibodies
against exposed epitopes inhibited the enzymatic activity of PSA.
The results suggested that binding of anti-PSA MAb to PSA
induced conformational changes leading to loss of enzymatic
activity ofPSA.
At present, there are three areas of main interest related to the
design ofPSA immunoassays: ultrasensitivity, equimolar response
assays (i.e. assays with the same molar response for F-PSA and
PSA-ACT) and assays for specific determination of the different
serological forms of PSA. The novel luminometric and fluoro-
metric detection methods and high-affinity antibodies make a
lower limit ofdetection (LLD) <0.005 ,ug 1-' possible, but the clin-
ical need for sensitivity of PSA assays indicates the need for
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further clinical studies (Vessella, 1993; Vessella and Lange 1993;
Yu and Diamanidis, 1993; Prestigiacomo and Stamey, 1994). The
detailed specificity of the immunoreagents is of great importance
for determination of PSA in the ultrasensitive range to exclude
determination of other members of the kallikrein gene family.
The terms equimolar and skewed-response assays have been
introduced to describe the differences in molar response between
F-PSA and PSA-ACT of immunoassays (Graves 1993).
Differences in the molar response for F-PSA and PSA-ACT may
partly explain the discordant results between assays based on
monoclonal antibodies (mono-mono assays), polyclonal anti-
bodies (poly-poly assays) or assays using both mono-and poly-
clonal antibodies (mono-poly assays). In poly-poly or mono-poly
assays, non-equimolar response may be obtained because addi-
tional epitopes are available for the polyclonal antibodies in F-
PSA compared with PSA-ACT thus leading to an overestimation
of the F-PSA fraction. However, the problem of non-equimolar
response is also evident in mono-mono assays, and diagnostic kits
using mono-mono design with large differences in molar response
between F-PSA and PSA-ACT are available. Reports have
suggested that poly-mono assays may reflect the clinical course of
prostate cancer more accurately than mono-mono assays
(Bluestein et al, 1992) and may also be less sensitive towards
interference from heterophilic antibodies than mono-mono assays
(Slota et al, 1994). Thus, the proper choice of monoclonal anti-
bodies is of major importance for the design of immunoassays
giving equimolar response for F-PSA and PSA-ACT and
maximum recognition of the different forms of PSA in serum.
The combination of the MAbs of Group A resulted in several
sandwich assays with similar molar response for F-PSA and
PSA-ACT. In particular the combination of MAbs of Group AIb,
All, AIII and AV resulted in highly sensitive assays (LLD < < 0.01
ig 1-1 using 25 gl of sample) for determination of total PSA (i.e. F-
PSA + PSA-ACT). The sandwich assays using PSA1O-PSA66,
PSA1O-PSA36, PSA66-PSA36 and PSA66-PSA42 MAbs gave an
equal response to the control sample containing only F-PSA and the
test sample containing = 60% F-PSA and = 40% PSA-ACT,
suggesting an equimolar response for F-PSA and PSA-ACT of
these assays. The equimolarity ofthe assays were also supported by
the identical dose-response and kinetics of purified F-PSA and
PSA-ACT. The combination of PSA42-PSA29 showed a lower
relative response in the test sample using 30 + 30 min incubation,
suggesting a non-equimolar response using this assay configuration,
while 60 + 60 min incubation showed almost the same response as
in the control sample. Further studies indicated that the non-
equimolar response of the PSA42-PSA29 assay was as a result of
the use ofPSA42 MAb as catching MAb. Thus, the proper choice of
immunoreagents, orientation ofthe antibodies as well as the general
assay design will influence the molar response between F-PSA and
PSA-ACT ofdifferent mono-mono sandwich PSA assays.
The initial findings of lower proportions of F-PSA in prostate
cancer than in BPH (Stenman et al, 1991; Christensson et al, 1993)
and the improved discrimination between BPH and prostate cancer
by determination of the ratio between F-PSA and total PSA or
PSA-ACT has focused interest on immunoassays specific for F-
PSA and/or PSA-ACT. In order to obtain optimal specificity of
the F-PSA-total PSA ratio, it is essential that the assays used for
determination ofF-PSA show minimal cross-reactivity between F-
PSA and PSA-ACT and that the total PSA assay gives an
equimolar response for F-PSA and PSA-ACT. The F-PSA specific
antibodies recognized the same or very similar antigenic domain
and could thus not be combined in sandwich assays. To our knowl-
edge, there are no F-PSA-specific antibodies available that can be
combined in sandwich pairs, suggesting that the F-PSA-specific
antigenic domain is relatively restricted. The combination ofthe F-
PSA specific MAbs and MAbs of Group Alla or AIIIb resulted in
highly sensitive and specific assays for determination of F-PSA.
The cross-reactivity of the preferred configurations was clearly <
1% (0.1-0.2%) suggesting that these assays would be suitable for
further clinical evaluation of determination of F-PSA. Enzyme
immunoassays for specific determination of F-PSA and total PSA
have been developed using the PSA30, PSAlO and PSA66 MAbs
(Nilsson et al, 1994) and used for determination of F-PSA and the
ratio between F-PSA and total PSA in BPH, prostate cancer and
healthy individuals (Nilsson et al, 1994a).
The MAb directed against the ACT portion of the PSA-ACT
complex could be used as detecting MAb together with the
catching MAb of group A for the development of sensitive and
specific sequential sandwich assays for determination of
PSA-ACT. Determination of the ratio between F-PSA and
PSA-ACT instead of F-PSA-T-PSA ratio would theoretically
further improve the discrimination between BPH and CAP.
However, assays using anti-ACT antibodies as tracer may show
severe background problems because ofnon-specific adsorption of
cathepsin G and/or ACT to plastic surfaces, resulting in binding of
the anti-ACT tracer; this has limited the practical usefulness ofthis
assay design for specific determination ofPSA-ACT (Leinonen et
al, 1993). Therefore, our approach for the development of
PSA-ACT-specific assays is to try to establish MAbs specific for
the PSA-ACT complex without reactivity with active ACT and to
use these antibodies for development ofPSA-ACT-specific assays
which should not give problems related to unspecific adsorption of
an anti-ACT tracer.
At present, there are independent studies using different
immunological reagents and patient materials (Nilsson et al,
1994b; Wang et al, 1994; Prestigiacomo and Stamey, 1995) which
have confirmed the initial finding that specific determination of
different serological forms of PSA may significantly improve the
discrimination between benign and malignant prostate disease
(Stenman et al, 1991; Christensson et al, 1993). However, the exact
molecular differences and a biological explanation for the differ-
ence in PSA between BPH and prostate cancer has so far not been
elucidated. Carefully characterized monoclonal antibodies directed
against different antigenic domains of PSA may be useful not only
for development of immunoassays for determination of different
serological forms of PSA but also for the further immunological
characterization of the different forms of PSA. The 'F-PSA'
fraction may be heterogeneous containing different forms ofenzy-
matically inactive PSA. Preliminary studies have suggested differ-
ences in the proteolytic activity of PSA in serum from healthy
individuals and BPH compared with subjects with prostate cancer
(Paus et al, 1995); this could explain the different proportions ofF-
PSA between BPH and CAP. The detailed biochemical and
immunological characterization of PSA and/or PSA-related
substances will be needed to further clarify the 'true' biochemical
and molecular nature ofthe different serological forms ofPSA.
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ABBREVIATIONS
PSA, prostate-specific antigen; F-PSA, free PSA, i.e. PSA not in
complex with any protease inhibitor; PSA-ACT, PSA in complex
with a,-anti-chymotrypsin; PSA-a2M, PSA in complex with cY-
macroglobulin; kDa, kilodalton; SDS-PAGE, sodiumdodecylsulphate
polyacrylamide electrophoresis; Delfia, dissociation enhanced fluoro-
immunoassay; ATCC, American Type Culture Collection; DMEM,
Dulbecco's modified Eagle medium; MTP, microtitre plate; HRP,
horseradish peroxidase; OPD, orthophenyl diamine; LLD, lower limit
of detection; BPH, benign prostatic hyperplasia; CAP, cancer of the
prostate; TTBS, tris-buffered saline containing Tween 20.
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